½ÃÀ庸°í¼­
»óǰÄÚµå
1792479

¼¼°èÀÇ ½ÉÀå º¸Ã¶ ±â±â ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)

Cardiac Prosthetic Devices Market Report by Product Type (Valves, Pacemakers, Implantable Pacemakers, External Pacemakers, and Others), End-User (Hospitals, Clinics and Cardiac Centers, Ambulatory Surgical Centers, and Others), and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 149 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ½ÉÀå º¸Ã¶ ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â 72¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ¾ÕÀ¸·Î IMARC GroupÀº 2033³â±îÁö 129¾ï ´Þ·¯¿¡ À̸£°í, 2025-2033³â±îÁö ¼ºÀå·ü(CAGR)Àº 6.42%°¡ µÉ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¼ÒÇü ÆäÀ̽º¸ÞÀÌÄ¿¿Í ¹«ºÀÇÕ ¹ëºê ´ëü¼úÀÇ °³¹ß, Àúħ½À(MI) ÀýÂ÷¿¡ ´ëÇÑ °æ»ç Áõ°¡, ´ëÁßµé »çÀÌÀÇ ½ÉÇ÷°ü Àå¾ÖÀÇ À¯º´·üÀÇ »ó½ÂÀº ½ÃÀåÀ» ÃßÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù.

½ÉÀå º¸Ã¶ ±â±â´Â ½ÉÀåÀÇ Á¤»óÀûÀÎ ±â´ÉÀ» ´ëüÇϰųª º¸Á¶Çϵµ·Ï ¼³°èµÈ Àΰø ±â±â ¹× ÀÓÇöõÆ®¸¦ ÀǹÌÇÕ´Ï´Ù. ½ÉºÎÀü, ÆÇ¸·Áõ, ¼±Ãµ¼º ½ÉÀå Áúȯ µî ´Ù¾çÇÑ ½ÉÀå ÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. Àΰø ½ÉÀå ¹ëºê¿Í ±â°èÀû ¼øÈ¯ º¸Á¶ ±â±âÀÇ µÎ À¯Çü·Î Å©°Ô ³ª´¹´Ï´Ù. Àΰø ½ÉÀå ÆÇ¸·Àº ¼Õ»óµÇ°Å³ª ¾ÆÇ ½ÉÀå ÆÇ¸· ´ë½Å »ç¿ëµÇ¾î ½ÉÀåÀ» ÅëÇÑ Á¤»óÀûÀÎ Ç÷·ù¸¦ ȸº¹½Ãŵ´Ï´Ù. ÇÑÆí, ±â°èÀû ¼øÈ¯ º¸Á¶ ±â±â´Â ½ÉÀåÀÇ ÆßÇÁ ±â´ÉÀ» º¸Á¶Çϰųª ´ëüÇÏ´Â µ¥ »ç¿ëµÇ¸ç, À̽Ŀ¡ ±³·®À¸·Î »ç¿ëÇϰųª ½ÉÀå À̽Ŀ¡ ºÎÀû°ÝÇÑ È¯ÀÚÀÇ Àå±âÀûÀÎ ÇØ°áÃ¥À¸·Î »ç¿ëµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¶ÇÇÑ »ýü ÀûÇÕ¼º Àç·á·Î Á¦Á¶µÇ°í ½ÉÀåÀÇ ±¸Á¶¿Í ±â´ÉÀ» ÀçÇöÇϵµ·Ï ¸é¹ÐÇÏ°Ô ¼³°èµÇ¾î ȯÀÚÀÇ ½ÉÀå ±â´É°ú »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

ÀÌ »ê¾÷À» °ßÀÎÇÏ´Â °ÍÀº ¼¼°è Àα¸ÀÇ °í·ÉÈ­ÀÔ´Ï´Ù. Àα¸ÀÇ °í·ÉÈ­°¡ ÁøÇàµÊ¿¡ µû¶ó ½ÉÇ÷°ü ÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÏ°í ½ÉÀå º¸Ã¶ ±â±â ¼ö¿ä°¡ Áõ°¡ÇÕ´Ï´Ù. °Ô´Ù°¡ ÀÇ·á±â¼ú°ú ¼ö¼ú±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ½ÉÇ÷°üÁúȯ ȯÀÚÀÇ »ýÁ¸À²ÀÌ Çâ»óµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ ±â±â¿¡ ´ëÇÑ È¯ÀÚ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²², ½ÉÇ÷°ü°èÀÇ °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í ´ëÁßµé »çÀÌÀÇ Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼ºÀÌ Á¦Ç° ¼ö¿ä¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ´Â »îÀÇ ÁúÀ» Çâ»ó½ÃŰ°í »ýÁ¸ ±â°£À» ¿¬ÀåÇϱâ À§ÇØ ½ÉÀå º¸Ã¶ ±â±âÀÇ »ç¿ëÀ» Æ÷ÇÔÇÑ Àû½Ã °³ÀÔÀ» ¿ä±¸Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÇコÄÉ¾î ºÎ¹®ÀÇ Áö¼ÓÀûÀÎ ¹ßÀü°ú ÁÖ¿ä ±â¾÷ÀÌ ¼öÇàÇÏ´Â ±¤¹üÀ§ÇÑ R&D(R&D) Ȱµ¿°ú °°Àº ±âŸ ¿äÀε鵵 ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

½ÉÀå º¸Ã¶ ±â±â ½ÃÀå µ¿Çâ ¹× ÃËÁø¿äÀÎ

½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü°ú ÀÎÁöµµ Çâ»ó

°ü»ó µ¿¸Æ Áúȯ, ½ÉºÎÀü, ½ÉÀå ÆÇ¸·Áõ°ú °°Àº ½ÉÇ÷°ü ÁúȯÀº Àü ¼¼°èÀûÀ¸·Î ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿äÀÎÀ̵Ǿú½À´Ï´Ù. ¶ÇÇÑ, ½ÉÀå Áúȯ, ¿¹¹æ Á¶Ä¡ ¹× Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡´Â ½ÉÇ÷°ü ÁúȯÀÇ Á¶±â ¹ß°ß°ú Áø´ÜÀ¸·Î À̾îÁý´Ï´Ù. ½ÉÃÊÀ½ÆÄ¿Í ½ÉÀå MRI¿Í °°Àº °í±Þ ¿µ»ó Áø´Ü ±â¼úÀ» Æ÷ÇÔÇÑ Áø´Ü ´É·ÂÀÇ Çâ»óÀº Á¤È®ÇÑ Áø´Ü°ú ½ÉÀå º¸Ã¶ ±â±âÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö Àִ ȯÀÚÀÇ ½Äº°À» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ±¹¹ÎÀÇ Àǽİú ¸¹Àº Áúº´ÀÇ À¯º´·ü »ó½ÂÀÌ ÇÔ²² Á¦Ç° ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´õ ¸¹Àº ȯÀÚµéÀÌ Á¶±â¿¡ CVD·Î Áø´ÜµÇ°í, Àΰø ½ÉÀåÀ» Æ÷ÇÔÇÑ °³ÀÔÀ¸·ÎºÎÅÍ ÇýÅÃÀ» ¹ÞÀ» ¼ö Àִ ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

À¯¸®ÇÑ »óȯ ½ÃÃ¥ÀÇ ½Ç½Ã

Áø·á º¸»óÀº ½ÉÀå º¸Ã¶ ±â±âÀÇ Ã¤¿ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤ºÎÀÇ °Ç°­ °ü¸® ½Ã½ºÅÛ ¹× ¹Î°£ º¸Çè Á¦°ø¾÷ü°¡ Á¦°øÇϴ ȣÀÇÀûÀÎ »óȯ Á¶Ä¡´Â °Ç°­ °ü¸® Á¦°ø¾÷ü°¡ ÀÌ·¯ÇÑ Àåºñ¿Í Ä¡·á¸¦ ȯÀÚ¿¡°Ô Á¦°øÇÏ´Â µ¿±â ºÎ¿©ÀÔ´Ï´Ù. À̴ ȯÀÚÀÇ °æÁ¦Àû À庮À» ÁÙÀÌ°í ½ÉÀå º¸Ã¶ ±â±âÀÇ »ç¿ëÀ» ÃËÁøÇÏ¿© ½ÃÀå ¼ºÀåÀ» À§ÇÑ È¯°æÀ» Á¶¼ºÇÕ´Ï´Ù. °Ô´Ù°¡ Áúº´ ºÎ´ã Áõ°¡¿Í ÀÇ·á ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ ¼¼°è¿¡¼­ ÇコÄɾî ÁöÃâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÇ·áºñ Áõ°¡´Â ½ÉÀå º¸Ã¶ ±â±âÀÇ ÇÕ¸®ÀûÀÎ °¡°Ý°ú Á¢±Ù¼º¿¡ ±â¿©Çϸç ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô ³Î¸® »ç¿ëµË´Ï´Ù. ÀÌ ¿Ü¿¡µµ ½ÃÀå ÁøÃâ±â¾÷Àº ÆÄÆ®³Ê½Ê, Çù¾÷, ÆÇ¸Å¸ÁÀ» ±¸ÃàÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÉÀå ¼ö¼ú ±â¼ú°ú ±â±âÀÇ ²÷ÀÓ¾ø´Â ±â¼ú Çõ½Å

Àúħ½À ¼ö¼ú, ·Îº¿ Áö¿ø ¼ö¼ú, °æ Ä«Å×ÅÍ ÀÎÅͺ¥¼Ç°ú °°Àº ½ÉÀå ¼ö¼ú ±â¼úÀÇ ²÷ÀÓ¾ø´Â Áøº¸´Â ´Ù¾çÇÑ ½ÉÀå ÁúȯÀÇ Ä¡·á ¹üÀ§¸¦ È®´ëÇØ ¿Ô½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ½ÉÀå ÆÇ¸·, º¸Á¶ Àΰø ½ÉÀå(VAD), ½É¹Ú Á¶À²±â µî ÀÌ·¯ÇÑ ÀýÂ÷¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ»ÇÏ´Â Á¦Ç°ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â¼úÀÇ ±Þ¼ÓÇÑ Áøº¸´Â ½ÉÀå º¸Ã¶ ±â±âÀÇ µðÀÚÀΰú ±â´É¿¡ Çõ¸íÀ» °¡Á®¿Ô½À´Ï´Ù. ¿¹¸¦ µé¾î, °æ Ä«Å×ÅÍ ½ÉÀå ÆÇ¸·ÀÇ °³¹ßÀº ħ½ÀÀÌ ÀûÀº ÆÇ¸· ġȯ¼úÀ» °¡´ÉÇÏ°Ô Çϰí, ȯÀÚÀÇ ¿Ü»ó ¹× ȸº¹ ½Ã°£À» ´ÜÃà½ÃÄ×½À´Ï´Ù. ¶ÇÇÑ ½ÉÀå¹Úµ¿±â¿Í À̽ÄÇü Á¦¼¼µ¿±â(ICD)¿¡ ¹«¼± ¿¬°á, ¿ø°Ý ¸ð´ÏÅ͸µ ±â´É, ÷´Ü ¼¾¼­°¡ ÅëÇյǾî ȯÀÚÀÇ Äɾî¿Í °á°ú°¡ °³¼±µÇ¾î ½ÃÀå Àü¸ÁÀº ¹à½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ½ÉÀå º¸Ã¶ ±â±â ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç° À¯Çüº°

  • ¹ëºê
    • ÁÖ¿ä À¯Çü
      • ±â°è ¹ëºê
      • Á¶Á÷ ¹ëºê
      • ½ºÅÙÆ®½Ä Á¶Á÷ ¹ëºê
      • ½ºÅÙÆ®¸®½º »ýü ¹ëºê
      • °æ Ä«Å×ÅÍ ¹ëºê
  • ÆäÀ̽º¸ÞÀÌÄ¿
  • ÀÓº£µðµåÇü ÆäÀ̽º¸ÞÀÌÄ¿
    • ÁÖ¿ä À¯Çü
      • ½Ì±Û è¹ö ¹èÅ͸® ÆäÀ̽º¸ÞÀÌÄ¿
      • µà¾ó è¹ö ¹èÅ͸® ÆäÀ̽º¸ÞÀÌÄ¿
      • Æ®¸®Çà è¹ö ¹èÅ͸® ÆäÀ̽º¸ÞÀÌÄ¿
  • ü¿Ü ÆäÀ̽º¸ÞÀÌÄ¿
  • ±âŸ

Á¦7Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø, Ŭ¸®´Ð, ½ÉÀå ¼¾ÅÍ
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ºÐ¼® : ±¹°¡º°

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Abbott Laboratories
    • BIoTronik
    • Boston Scientific Corporation
    • Edwards Lifesciences Corporation
    • Lepu Medical Technology Co. Ltd.
    • Medtronic Inc.
    • Meril Life Sciences Pvt. Ltd.
    • Siemens Healthcare GmbH
    • Sorin Group
    • St. Jude Medical Inc.
JHS 25.08.26

The global cardiac prosthetic devices market size reached USD 7.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.42% during 2025-2033. The development of compact pacemakers and suture-less valve replacements, the growing inclination toward minimally invasive (MI) procedures, and the rising prevalence of cardiovascular disorders among the masses are some of the major factors propelling the market.

Cardiac prosthetic devices refer to artificial devices or implants designed to replace or assist the normal functioning of the heart. They are used in the treatment of various heart conditions, such as heart failure, valve disorders, or congenital heart defects. They can be broadly categorized into two types, artificial heart valves and mechanical circulatory support devices. Artificial heart valves are used to replace damaged or diseased heart valves, restoring normal blood flow through the heart. On the other hand, mechanical circulatory support devices are used to assist or replace the pumping function of the heart, often employed as a bridge to transplantation or as a long-term solution for patients ineligible for heart transplantation. Additionally, they are manufactured of biocompatible materials and are meticulously designed to replicate the structure and function of the heart, thereby improving the patient's cardiac function and quality of life.

The industry is driven by the aging global population. As the population continues to age, the incidence of cardiovascular diseases increases, leading to a higher demand for cardiac prosthetic devices. Additionally, continual advancements in medical technology and surgical techniques have improved the survival rates of patients with cardiovascular diseases, this is creating a larger patient pool for these devices. Along with this, the increasing awareness about cardiovascular health and the availability of treatment options among the masses is fueling the product demand. Also, patients are seeking timely interventions, including the use of cardiac prosthetic devices, to improve their quality of life and prolong survival, which is positively influencing the market. Other factors, including continual developments in the healthcare sector and extensive research and development (R&D) activities conducted by key players, are also positively influencing the market.

Cardiac Prosthetic Devices Market Trends/Drivers:

Increasing Prevalence of Cardiovascular Diseases and their Awareness

Cardiovascular diseases, including coronary artery disease, heart failure, and valvular heart diseases, are significant contributors to morbidity and mortality across the globe. Additionally, the increasing awareness about heart diseases, preventive measures, and the availability of treatment options has led to earlier detection and diagnosis of cardiovascular conditions. Improved diagnostic capabilities, including advanced imaging techniques, such as echocardiography and cardiac MRI, facilitate accurate diagnosis and identification of patients who may benefit from cardiac prosthetic devices. The combination of public awareness and the rising prevalence of numerous diseases has led to an increasing product demand. As more individuals are diagnosed with CVDs at an earlier stage, there is a growing pool of patients who could benefit from interventions involving cardiac prosthetics.

The Implementation of Favorable Reimbursement Policies

Reimbursement plays a vital role in the adoption of cardiac prosthetic devices. Favorable reimbursement policies offered by government healthcare systems and private insurance providers incentivize healthcare providers to offer these devices and procedures to their patients. This creates a conducive environment for market growth, as it reduces financial barriers for patients and promotes the use of cardiac prosthetic devices. In addition, the rising disease burden, and advances in medical technology are increasing healthcare expenditure across the globe. This higher healthcare spending is contributing to the affordability and accessibility of cardiac prosthetic devices, making them more widely available to patients in need. Besides this, market players are establishing partnerships, collaborations, and distribution networks, which are acting as another growth-inducing factor.

Continual Technological Innovations in Cardiac Surgery Techniques and Devices

Continuous advancements in cardiac surgical techniques, such as minimally invasive procedures, robotic-assisted surgeries, and transcatheter interventions, have expanded the scope of treating various cardiac conditions. These advancements have increased product utilization, including heart valves, ventricular assist devices (VADs), and pacemakers, as they play a crucial role in these procedures. Rapid advancements in technology have revolutionized the design and functionality of cardiac prosthetic devices. For instance, the development of transcatheter heart valves has enabled less invasive valve replacement procedures, reducing patient trauma and recovery time. Additionally, the integration of wireless connectivity, remote monitoring capabilities, and advanced sensors in pacemakers and implantable cardioverter-defibrillators (ICDs) has improved patient care and outcomes, creating a positive market outlook.

Cardiac Prosthetic Devices Industry Segmentation:

Breakup by Product Type:

  • Valves
    • Mechanical Valve
    • Tissue Valve
    • Stented Tissue Valve
    • Stentless Tissue Valve
    • Transcatheter Valve
  • Pacemakers
  • Implantable Pacemakers
    • Single-Chamber Battery Pacemaker
    • Dual-Chamber Battery Pacemaker
    • Triple-Chamber Battery Pacemaker
  • External Pacemakers
  • Others

Valves dominate the market

Continual technological advancements in valve design and materials have improved the durability, functionality, and overall performance of devices, leading to greater acceptance and adoption. Additionally, the increasing focus on minimally invasive procedures and the development of transcatheter heart valve replacement techniques are positively influencing the demand for valve products.

Additionally, continuous advancements in medical technology have led to the development of innovative pacemaker devices with improved features and functionalities, including wireless connectivity and remote monitoring capabilities, which further drive market growth. Moreover, the rising prevalence of lifestyle-related diseases, such as obesity and diabetes, which are risk factors for heart ailments, is fueling the demand for pacemakers across the globe.

Breakup by End-User:

  • Hospitals, Clinics and Cardiac Centers
  • Ambulatory Surgical Centers
  • Others

Hospitals, clinics and cardiac centers hold the largest share in the market

The increasing usage of these devices in hospitals, clinics, and cardiac centers can be attributed to the continual advancements in medical technology and surgical techniques. The continuous development of innovative devices, such as artificial heart valves and implantable pacemakers, enables healthcare providers to offer improved treatment options to patients. Furthermore, various government initiatives and healthcare reforms aimed at enhancing cardiovascular care and improving patient outcomes also serve as major market drivers for the end-users in the industry.

On the contrary, ambulatory surgical centers (ASCs) as end-users in the cardiac offer numerous advantages, such as cost-effectiveness, convenience, and reduced hospital stays, which are particularly appealing to patients seeking cardiac procedures. These centers provide a suitable environment for minimally invasive surgeries and outpatient treatments, aligning with the growing trend towards value-based healthcare. Additionally, advancements in technology have made it feasible to perform complex cardiac procedures in ASCs, further fueling the market demand in this segment over the forecast period.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest the cardiac prosthetic devices market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The market in North America is driven by the increasing prevalence of cardiovascular diseases and the growing aging population. As heart-related conditions become more common, the need for devices such as heart valves, pacemakers, and implantable defibrillators is growing. Additionally, the healthcare system across the region focuses on quality healthcare delivery and reimbursement support for medical devices also plays a significant role in the growth of the market. Moreover, research and development efforts aimed at developing innovative and minimally invasive prosthetic devices are significantly supporting the market.

On the contrary, Asia Pacific is estimated to expand further in this domain in the coming years due to the aging population and changing lifestyles. In confluence with this, advancements in healthcare infrastructure and the rising disposable income in several countries within the Asia Pacific region have improved access to medical treatments and increased affordability. Furthermore, ongoing technological advancements and innovations in the field are driving the market in Asia Pacific.

Competitive Landscape:

The market is experiencing significant growth due to the continual advancements in medical technology and surgical procedures leading to the development of innovative and more efficient devices. Additionally, the integration of digital health technologies is creating opportunities for companies to offer remote monitoring solutions and personalized healthcare services, enhancing patient outcomes and increasing the overall value proposition of their products. Also, numerous companies are developing tailored solutions to address specific patient needs, this is gaining prominence across the globe. Moreover, the development of 3D printing technology has further facilitated the production of patient-specific devices, allowing for better fit and improved functionality. Additionally, top companies are investing in research and development to create customizable solutions and collaborate with healthcare professionals to understand patient requirements, which is influencing the market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Biotronik
  • Boston Scientific Corporation
  • Edwards Lifesciences Corporation
  • Lepu Medical Technology Co. Ltd.
  • Medtronic Inc.
  • Meril Life Sciences Pvt. Ltd.
  • Siemens Healthcare GmbH
  • Sorin Group
  • St. Jude Medical Inc.

Key Questions Answered in This Report:

  • How has the global cardiac prosthetic devices market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global cardiac prosthetic devices market?
  • What is the impact of each driver, restraint, and opportunity on the global cardiac prosthetic devices market?
  • What are the key regional markets?
  • Which countries represent the most attractive cardiac prosthetic devices market?
  • What is the breakup of the market based on the product type?
  • Which is the most attractive product type in the cardiac prosthetic devices market?
  • What is the breakup of the market based on the end-user?
  • Which is the most attractive end-user in the cardiac prosthetic devices market?
  • What is the competitive structure of the global cardiac prosthetic devices market?
  • Who are the key players/companies in the global cardiac prosthetic devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cardiac Prosthetic Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Valves
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Mechanical Valve
      • 6.1.2.2 Tissue Valve
      • 6.1.2.3 Stented Tissue Valve
      • 6.1.2.4 Stentless Tissue Valve
      • 6.1.2.5 Transcatheter Valve
    • 6.1.3 Market Forecast
  • 6.2 Pacemakers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Implantable Pacemakers
    • 6.3.1 Market Trends
    • 6.3.2 Major Types
      • 6.3.2.1 Single-Chamber Battery Pacemaker
      • 6.3.2.2 Dual-Chamber Battery Pacemaker
      • 6.3.2.3 Triple-Chamber Battery Pacemaker
    • 6.3.3 Market Forecast
  • 6.4 External Pacemakers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by End-User

  • 7.1 Hospitals, Clinics and Cardiac Centers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ambulatory Surgical Centers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbott Laboratories
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Biotronik
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Boston Scientific Corporation
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Edwards Lifesciences Corporation
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Lepu Medical Technology Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Medtronic Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 Meril Life Sciences Pvt. Ltd.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 Siemens Healthcare GmbH
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Sorin Group
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 St. Jude Medical Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦